Literature DB >> 18821278

Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment.

V Brodszky, M Pentek, L Gulacsi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18821278     DOI： 10.1080/03009740802004966

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  4 in total

Review 1.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

2.  Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.

Authors:  Kristian Thorlund; Eric Druyts; J Antonio Aviña-Zubieta; Edward J Mills
Journal:  Biologics       Date:  2012-12-03

Review 3.  Efficacy and safety of adalimumab in ankylosing spondylitis.

Authors:  Aziza Mounach; Abdellah El Maghraoui
Journal:  Open Access Rheumatol       Date:  2014-08-13

Review 4.  Long-term use of adalimumab in the treatment of rheumatic diseases.

Authors:  Charalampos Papagoras; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Open Access Rheumatol       Date:  2009-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.